Pro-EMAP II is not primarily cleaved by caspase-3 and -7

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 282, Issue 6 26-6, 2002, Pages

  Zhang, F R ^a,b   Schwarz, M A ^a,b,c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Antiangiogenesis; Caspase 7; Endothelial monocyte activating polypeptide; Endothelial monocyte activating polypeptide II; Neovascularization; p43

Indexed keywords

CASPASE 3; CASPASE 7; ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II;

ANIMAL CELL; ARTICLE; CELL DIVISION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION;

EID: 0036080804     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00141.2001     Document Type: Article

References (22)

1. The endothelial monocyte-activating polypeptide II (EMAP II) is a substrate for caspase-7
2. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis
3. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapyinduced apoptosis is not dependent on Fas/Fas ligand interactions
4. Anti-angiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma
5. Tissue interactions mediate early events in pulmonary vasculogenesis
6. VEGF is deposited in the subepithelial matrix at the leading edge of branching airways and stimulates neovascularization in the murine embryonic lung
7. Endothelial-monocyte activating polypeptides (EMAPs): Tumor derived mediators which activate the host inflammatory response
8. Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II
9. Regulation of endothelial monocyte-activating polypeptide II release by apoptosis
10. A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor
11. The p43 component of the mammalian multi-synthetase complex is likely to be the precursor of the endothelial monocyte-activating polypeptide II cytokine
12. KEKE motifs. Proposed roles in protein-protein association and presentation of peptides by MHC class I receptors
13. Organotypic arrangement of mouse embryonic lung cells on a basement membrane extract: Involvement of laminin
14. Laminin alpha1 chain synthesis in the mouse developing lung: Requirement for epithelial-mesenchymal contact and possible role in bronchial smooth muscle development
15. Laminin fragment E4 inhibition studies: Basement membrane assembly and embryonic lung epithelial cell polarization requires laminin polymerization
16. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells
17. EMAP II inhibits lung neovascularization and airway epithelial morphogenesis
18. Caspases: Enemies within
19. Two distinct cytokines released from a human aminoacyl-tRNA synthetase
20. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelialmonocyte activating polypeptide II (EMAPII)
21. Temporo-spatial distribution of endothelial-monocyte activating polypeptide II, an anti-angiogenic protein, in the mouse embryo
22. Apoptosis, in human monocytic THP.1 cells, results in the release of cytochrome c from mitochondria prior to their ultracondensation, formation of outer membrane discontinuities and reduction in inner membrane potential